421 related articles for article (PubMed ID: 25449310)
1. Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients.
Rithirangsriroj K; Manchana T; Akkayagorn L
Gynecol Oncol; 2015 Jan; 136(1):82-6. PubMed ID: 25449310
[TBL] [Abstract][Full Text] [Related]
2. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
5. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Markman MR; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
[TBL] [Abstract][Full Text] [Related]
9. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
11. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
15. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Furukawa N; Kanayama S; Tanase Y; Ito F
Support Care Cancer; 2015 Nov; 23(11):3317-22. PubMed ID: 25947257
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
18. Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases.
Josefson A; Kreuter M
Rheumatology (Oxford); 2003 Oct; 42(10):1149-54. PubMed ID: 12777644
[TBL] [Abstract][Full Text] [Related]
19. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]